CL2020001183A1 - Implantes de liberación sostenida para reducir la presión intraocular con duración prolongada del efecto. - Google Patents

Implantes de liberación sostenida para reducir la presión intraocular con duración prolongada del efecto.

Info

Publication number
CL2020001183A1
CL2020001183A1 CL2020001183A CL2020001183A CL2020001183A1 CL 2020001183 A1 CL2020001183 A1 CL 2020001183A1 CL 2020001183 A CL2020001183 A CL 2020001183A CL 2020001183 A CL2020001183 A CL 2020001183A CL 2020001183 A1 CL2020001183 A1 CL 2020001183A1
Authority
CL
Chile
Prior art keywords
intraocular pressure
sustained
effect
prolonged duration
reduce intraocular
Prior art date
Application number
CL2020001183A
Other languages
English (en)
Spanish (es)
Inventor
Michael R Robinson
Marina Bejanian
Michelle Y Chen
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CL2020001183A1 publication Critical patent/CL2020001183A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Surgery (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)
CL2020001183A 2017-11-09 2020-05-05 Implantes de liberación sostenida para reducir la presión intraocular con duración prolongada del efecto. CL2020001183A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762583967P 2017-11-09 2017-11-09
US201862683337P 2018-06-11 2018-06-11

Publications (1)

Publication Number Publication Date
CL2020001183A1 true CL2020001183A1 (es) 2020-11-06

Family

ID=64457124

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001183A CL2020001183A1 (es) 2017-11-09 2020-05-05 Implantes de liberación sostenida para reducir la presión intraocular con duración prolongada del efecto.

Country Status (16)

Country Link
US (2) US20190192341A1 (https=)
EP (1) EP3706717A1 (https=)
JP (2) JP2021502366A (https=)
KR (1) KR20200086289A (https=)
CN (1) CN111315361A (https=)
AU (2) AU2018366214B2 (https=)
BR (1) BR112020009224A2 (https=)
CA (1) CA3080908A1 (https=)
CL (1) CL2020001183A1 (https=)
CO (1) CO2020006924A2 (https=)
IL (1) IL273946A (https=)
MX (2) MX2020004730A (https=)
PH (1) PH12020550550A1 (https=)
RU (1) RU2020113494A (https=)
SG (1) SG11202004126XA (https=)
WO (1) WO2019094652A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105682645B (zh) * 2013-10-31 2019-09-06 阿勒根公司 含前列腺酰胺的眼内植入物及其使用方法
GB2601922B (en) 2019-06-27 2024-04-24 Layerbio Inc Ocular device drub delivery systems
CA3166738A1 (en) 2020-02-06 2021-08-12 Charles D. Blizzard Travoprost compositions and methods for treating ocular diseases
EP3884929B1 (en) 2020-03-25 2023-06-14 Ocular Therapeutix, Inc. Ocular implant containing a tyrosine kinase inhibitor
WO2022011321A1 (en) 2020-07-10 2022-01-13 Allergan, Inc. Posterior chamber delivery device for sustained release implant
BR112023001073A2 (pt) * 2020-07-21 2023-03-07 Allergan Inc Implante intraocular com alto carregamento de prostamida
CN120897764A (zh) 2023-04-11 2025-11-04 视尔普斯眼科公司 包含阿西替尼多晶型物iv的眼部植入物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834498A (en) 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US7993634B2 (en) * 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
EP3085358B1 (en) * 2010-01-22 2017-11-01 Allergan, Inc. Intracameral sustained release therapeutic agent implants
US20120276186A1 (en) * 2011-04-29 2012-11-01 Ghebremeskel Alazar N Sustained release latanoprost implant
CN105682645B (zh) * 2013-10-31 2019-09-06 阿勒根公司 含前列腺酰胺的眼内植入物及其使用方法
MX2016007345A (es) * 2013-12-06 2016-12-09 Envisia Therapeutics Inc Implante intracameral para el tratamiento de una condicion ocular.
EP3324890A4 (en) * 2015-07-23 2019-06-19 Allergan, Inc. GLACO-TREATMENT VIA INTRAKAMERAL EYE IMPLANTS

Also Published As

Publication number Publication date
CA3080908A1 (en) 2019-05-16
BR112020009224A2 (pt) 2020-10-13
MX2023011426A (es) 2023-10-17
US20240130890A1 (en) 2024-04-25
JP2024032731A (ja) 2024-03-12
JP2021502366A (ja) 2021-01-28
CO2020006924A2 (es) 2020-06-19
CN111315361A (zh) 2020-06-19
AU2018366214A1 (en) 2020-05-14
PH12020550550A1 (en) 2021-03-22
RU2020113494A3 (https=) 2021-12-09
IL273946A (en) 2020-05-31
RU2020113494A (ru) 2021-12-09
KR20200086289A (ko) 2020-07-16
EP3706717A1 (en) 2020-09-16
US20190192341A1 (en) 2019-06-27
MX2020004730A (es) 2020-08-13
WO2019094652A1 (en) 2019-05-16
AU2018366214B2 (en) 2024-11-14
SG11202004126XA (en) 2020-06-29
US20240225893A9 (en) 2024-07-11
AU2024227541A1 (en) 2024-11-14

Similar Documents

Publication Publication Date Title
CL2020001183A1 (es) Implantes de liberación sostenida para reducir la presión intraocular con duración prolongada del efecto.
MX2020001340A (es) Modelos celulares y terapias para enfermedades oculares.
CL2021001228A1 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
MX2018003542A (es) Metodos para tratar presion intraocular con activadores de tie-2.
MX2018014763A (es) Suministro intraocular de farmacos.
PH12021550621A1 (en) Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
MX2018001918A (es) Aplicación cuantitativa periorbital de farmacos oftalmologicos.
MY177504A (en) Ophthalmic composition for the treatment of ocular infection
MX388927B (es) Formulación oftálmica que comprende citicolina transportada por liposomas para el tratamiento del glaucoma.
CL2021000580A1 (es) Uso de inhibidores de la caseina quinasa 1 para el tratamiento de enfermedades vasculares.
MX2020012014A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
MX2025000353A (es) Metodos para tratar el dolor de la superficie ocular
MX2023012758A (es) Composiciones y metodos para el tratamiento de la enfermedad ocular asociada con angiogenesis.
MX2017007578A (es) Farmacoterapia para prevenir o tratar glaucoma.
RU2014140798A (ru) Способ коррекции фиброзно-измененных фильтрационных подушек, возникающих в послеоперационном периоде при хирургии глаукомы
AR107460A1 (es) Gabapentina oftálmica para el tratamiento de las úlceras corneales
UY33562A (es) Agonistas de receptores de bradicinina y su utilización para el tratamiento de la hipertensión ocular y el glaucoma
IL282898A (en) Ophthalmic compounds and methods for treating skin and eye diseases
EP3445334C0 (en) NANOLIPOSOMES FOR PROLONGED ADMINISTRATION OF TACROLIMUS FOR THE TREATMENT OF ANTERIOR SEGMENT EYE DISEASES
WO2015200601A3 (en) Lymphangiogenesis inhibitors for cancer and for graft survival
ES1240340Y (es) Implante de drenaje en el tratamiento del glaucoma por el procedimiento de esclerectomia profunda no perforante
WO2022104102A3 (en) Materials and methods for treating corneal dysfunction
AR095516A1 (es) Implante intraocular que contiene prostamida